Status:
COMPLETED
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intrav...
Eligibility Criteria
Inclusion
- BMI 27-35 kg/m2
Exclusion
- Women of childbearing potential
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00331175
Start Date
July 1 2006
End Date
December 1 2006
Last Update
December 15 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States